文献速递胸部肿瘤

约克郡肺部筛查试验中肺癌筛查资格标准与肺癌检出率的前瞻性评估

Prospective Evaluation of Lung Cancer Screening Eligibility Criteria and Lung Cancer Detection in the Yorkshire Lung Screening Trial.
PubMed 文献 · J Thorac Oncol · 2024-12-19

约克郡肺部筛查试验前瞻性评估三种肺癌筛查资格标准,共邀请44957人,22814人接受资格评估,7826人符合至少一项标准。PLCOM2012≥1.51%标准下符合筛查比例及检出癌症比例均高于LLPv2≥5%和USPSTF2013。在等效人群中,两种风险模型检出无显著差异,但均优于USPSTF2013。

要点

  • PLCOM2012≥1.51%标准筛查资格比例28.0%,检出癌症比例91.1%,均高于其他两种标准。
  • LLPv2≥5%与USPSTF2013标准筛查资格比例分别为20.5%和18.9%,检出癌症比例分别为77.0%和62.8%。
  • 等效人群比较中,PLCOM2012和LLPv2检出比例分别为74.5%和71.3%,高于USPSTF2013的62.8%,两种风险模型间无显著差异。

核心结论

  • PLCOM2012≥1.51%标准在约克郡肺部筛查试验中识别出更多符合筛查条件者,并检出更多筛查发现的肺癌,优于LLPv2≥5%或USPSTF2013标准。
  • 在等效人群中,两种风险模型在肺癌检出方面无显著差异,且均比USPSTF2013更有效地选择筛查人群。

研究设计与样本

  • 约克郡肺部筛查试验为前瞻性评估肺癌筛查实施的研究,主要目标为前瞻性评估三种预设资格标准。
  • 研究对象为55至80岁、有吸烟史、对书面邀请作出回应并接受电话风险评估的个体。
  • 符合至少一项标准(PLCOM2012≥1.51%、LLPv2≥5%、USPSTF2013)者接受每两年一次的低剂量计算机断层扫描筛查。
  • 共邀请44957人,22814人回应并接受资格评估,其中7826人符合任一筛查标准。

主要发现

  • PLCOM2012≥1.51%、LLPv2≥5%和USPSTF2013标准下,回应者中符合筛查的比例分别为28.0%、20.5%和18.9%(每项比较P<0.0001)。
  • 三种标准下检出的所有癌症比例分别为91.1%、77.0%和62.8%(每项比较P≤0.0002)。
  • 当选择风险阈值使符合筛查人数相当时,PLCOM2012检出癌症比例为74.5%,LLPv2为71.3%,均高于USPSTF2013的62.8%(P=0.0002和P=0.032),但两种风险模型间无显著差异。
  • 将LLPv2风险阈值从5%降至2.5%(如当前英格兰肺癌筛查项目所用)以及降低USPSTF2021相比USPSTF2013的包年要求,增加了符合筛查的人数,但本研究未测量后续癌症检出情况。

关键数值与推荐

  • PLCOM2012≥1.51%、LLPv2≥5%、USPSTF2013为预定义的三种筛查资格标准。
  • PLCOM2012≥1.51%标准下符合筛查比例28.0%,检出癌症比例91.1%。
  • LLPv2≥5%标准下符合筛查比例20.5%,检出癌症比例77.0%。
  • USPSTF2013标准下符合筛查比例18.9%,检出癌症比例62.8%。
  • 等效人群比较中,PLCOM2012检出癌症比例74.5%,LLPv2为71.3%,USPSTF2013为62.8%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 将LLPv2风险阈值从5%降至2.5%以及降低USPSTF2021相比USPSTF2013的包年要求虽增加符合筛查人数,但本研究未测量后续癌症检出情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Low-dose computed tomography screening for lung cancer reduces lung cancer mortality, but there is a lack of international consensus regarding the optimal eligibility criteria for screening. The Yorkshire Lung Screening Trial was designed to evaluate lung cancer screening (LCS) implementation, and a primary objective was prospective evaluation of three predefined eligibility criteria. METHODS: Individuals who had ever smoked, aged 55 to 80 years, who responded to written invitation, underwent telephone risk assessment and if eligible by at least one criterion (PLCOM2012 ≥ 1.51%, LLPv2 ≥ 5%, USPSTF2013) were offered biennial low-dose computed tomography screening. RESULTS: Of 44,957 individuals invited, 22,814 responded and underwent eligibility assessment, of whom a total of 7826 were eligible according to any of the three LCS criteria. Comparing PLCOM2012 ≥ 1.51%, LLPv2 ≥ 5%, and USPSTF2013, the proportions of responders eligible for screening were 28.0%, 20.5%, and 18.9%, respectively (p < 0.0001 for each comparison), and the proportion of all cancers detected 91.1%, 77.0%, and 62.8%, respectively (p ≤ 0.0002 for each comparison). When risk thresholds were selected to result in equivalent numbers of people eligible for screening, cancer detection proportions were higher for PLCOM2012 (74.5%) and LLPv2 (71.3%) than USPSTF2013 (62.8%) (p = 0.0002 and p = 0.032, respectively), but there was no significant difference between the two risk models. Reducing the LLPv2 risk threshold from 5% to 2.5% (as currently used in the English LCS program) and reducing the pack-year requirement for the USPSTF2021 versus the USPSTF2013 criteria increased the numbers eligible for screening, but subsequent cancer yield was not measured in this study. CONCLUSION: The PLCOM2012 ≥ 1.51% criteria identified more people eligible for screening in Yorkshire Lung Screening Trial and resulted in more screen-detected lung cancers than LLPv2 ≥ 5% or USPSTF2013. When compared in equivalent populations, there was no significant difference between risk models in terms of lung cancer detection and each appeared more efficient at screening population selection than USPSTF2013.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Gabe R, Crosbie PAJ, Vulkan D, et al. Prospective Evaluation of Lung Cancer Screening Eligibility Criteria and Lung Cancer Detection in the Yorkshire Lung Screening Trial. J Thorac Oncol. 2024. PMID: 39709114. doi:10.1016/j.jtho.2024.12.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。